ConductScience.org, home

Paper32611684

Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models.

Jiang Q and 12 others. Sci Transl Med, 2020. Cited by 46 papers, by iCite.

Cite this record

ConductScience Library. Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models. Papers, record 32611684. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32611684

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models.
PubMed
Journal
Sci Transl Med
PubMed
Year
2020
PubMed
Publication types
Journal Article, Research Support, N.I.H., Intramural
PubMed
Citations, by iCite
46
iCite
Relative citation ratio, by iCite
1.72
iCite
Revised in PubMed
2025-05-30
PubMed

Authors13

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Jiang QQunhttps://orcid.org/0000-0003-1611-2595
2Ghafoor AAzam
3Mian IIdrees
4Rathkey DDanielhttps://orcid.org/0000-0002-6149-277X
5Thomas AAnishhttps://orcid.org/0000-0003-3293-3115
6Alewine CChristinehttps://orcid.org/0000-0003-1661-0957
7Sengupta MManjistha
8Ahlman MAMark A
9Zhang JJinglihttps://orcid.org/0000-0002-8590-5233
10Morrow BBetsyhttps://orcid.org/0000-0001-7112-1078
11Steinberg SMSeth Mhttps://orcid.org/0000-0002-8280-551X
12Pastan IIrahttps://orcid.org/0000-0002-9223-0270
13Hassan RRaffithttps://orcid.org/0000-0002-4012-3633

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
ImmunotoxinsMajor topic
Lung NeoplasmsMajor topic
MesotheliomaMajor topic
Animals
B7-H1 Antigen
CD8-Positive T-Lymphocytes
GPI-Linked Proteins
Humans
Immunoconjugates
Leukocytes, Mononuclear
Mesothelin
Mice
Prospective Studies

Source PubMed

Download CSV of topics

Grants8

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
Z01 BC010020Intramural NIH HHSUnited StatesZ01BC010020PubMedNIH RePORTER
Z01 BC010816Intramural NIH HHSUnited StatesZIABC010816PubMed and NIHNIH RePORTER
Z01 SC007202Intramural NIH HHSUnited StatesZ01SC007202PubMedNIH RePORTER
ZIA BC010816Intramural NIH HHSUnited StatesZIABC010816PubMed and NIHNIH RePORTER
ZIABC008753NIHNIH RePORTER
ZIABC011652NIHNIH RePORTER
ZIDBC011540NIHNIH RePORTER
ZIEBC011653NIHNIH RePORTER

Download CSV of grants

References39

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130931305Immune Cell Infiltration of the Primary Tumor, Not PD-L1 Status, Is Associated With Improved Response to Checkpoint Inhibition in Metastatic Melanoma.Front Med (Lausanne)2019https://conductscience.org/library/papers/30931305PubMed
230441807SS1P Immunotoxin Induces Markers of Immunogenic Cell Death and Enhances the Effect of the CTLA-4 Blockade in AE17M Mouse Mesothelioma Tumors.Toxins (Basel)2018https://conductscience.org/library/papers/30441807PubMed
328729154Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.Lancet Oncol2017https://conductscience.org/library/papers/28729154PubMed
425348003Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression.Nat Commun2014https://conductscience.org/library/papers/25348003PubMed
527863199Mesothelin Immunotherapy for Cancer: Ready for Prime Time?J Clin Oncol2016https://conductscience.org/library/papers/27863199PubMed
622850877ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression.J Clin Invest2012https://conductscience.org/library/papers/22850877PubMed
712860938Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.J Clin Oncol2003https://conductscience.org/library/papers/12860938PubMed
829958801Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy.Immunity2018https://conductscience.org/library/papers/29958801PubMed
91351045Frequent expression of the tumor antigen CAK1 in squamous-cell carcinomas.Int J Cancer1992https://conductscience.org/library/papers/1351045PubMed
1028878676PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome.Front Pharmacol2017https://conductscience.org/library/papers/28878676PubMed
1124824231Discovery of mesothelin and exploiting it as a target for immunotherapy.Cancer Res2014https://conductscience.org/library/papers/24824231PubMed
1218771959Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy.Clin Immunol2008https://conductscience.org/library/papers/18771959PubMed
1326463707New Life for Immunotoxin Cancer Therapy.Clin Cancer Res2016https://conductscience.org/library/papers/26463707PubMed
1419097774New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).Eur J Cancer2009https://conductscience.org/library/papers/19097774PubMed
1510778980Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.Clin Cancer Res2000https://conductscience.org/library/papers/10778980PubMed
1626719230Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.Lancet2016https://conductscience.org/library/papers/26719230PubMed
1728650338IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.J Clin Invest2017https://conductscience.org/library/papers/28650338PubMed
1828291584Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.Lancet Oncol2017https://conductscience.org/library/papers/28291584PubMed
1930244849Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma.J Thorac Oncol2018https://conductscience.org/library/papers/30244849PubMed
2024321581Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.Lung Cancer2014https://conductscience.org/library/papers/24321581PubMed

See all 39 referencesDownload CSV of references

Cited by38

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 46 citations.

PMIDTitleJournalYearIn PapersSource
41425223Mapping drug distribution using CT imaging following direct tissue injection in ex vivo liver: informing clinical implementation.CVIR Oncol2025https://conductscience.org/library/papers/41425223PubMed
41400642Novel perspectives on MSLN-targeted cancer therapy: from molecular mechanisms to clinical translation.Cancer Biol Ther2025https://conductscience.org/library/papers/41400642PubMed
41335396Decoding the role of mesothelin in tumor dynamics and targeted treatment innovations.Mol Biomed2025https://conductscience.org/library/papers/41335396PubMed
40682047Rapid diagnostic imaging and targeted immunotoxin delivery in aggressive prostate cancer using CEACAM5-specific nanobodies.J Nanobiotechnology2025https://conductscience.org/library/papers/40682047PubMed
40679256Hyponatremia predicts immunotherapy resistance in biliary tract cancer.Hum Vaccin Immunother2025https://conductscience.org/library/papers/40679256PubMed
40506494[Recent Advances in Medical Treatment of Malignant Pleural Mesothelioma].Zhongguo Fei Ai Za Zhi2025https://conductscience.org/library/papers/40506494PubMed
40406146A conceptual exploration on the synergistic anti-tumor effects of high-order combination of OHSV2-DSTEFAP5/CD3, CAR-T cells, and immunotoxins in hepatocellular carcinoma.Front Immunol2025https://conductscience.org/library/papers/40406146PubMed
40315330Robust differentiation of NK cells from MSLN.CAR-IL-15-engineered human iPSCs with enhanced antitumor efficacy against solid tumors.Sci Adv2025https://conductscience.org/library/papers/40315330PubMed
40135833GRP78 Nanobody-Directed Immunotoxin Activates Innate Immunity Through STING Pathway to Synergize Tumor Immunotherapy.Adv Sci (Weinh)2025https://conductscience.org/library/papers/40135833PubMed
40010770Targeting mesothelin-CD24 axis repolarizes tumor-associated macrophages to potentiate PD-1 blockade therapy in high-grade serous ovarian cancer.J Immunother Cancer2025https://conductscience.org/library/papers/40010770PubMed
39981134Potentiating intratumoral therapy with immune checkpoint inhibitors: shifting the paradigm of multimodality therapeutics.Immunooncol Technol2025https://conductscience.org/library/papers/39981134PubMed
38893092Targeted Therapy in Mesotheliomas: Uphill All the Way.Cancers (Basel)2024https://conductscience.org/library/papers/38893092PubMed
38706610Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers.Front Oncol2024https://conductscience.org/library/papers/38706610PubMed
38610930Emerging New Targets in Systemic Therapy for Malignant Pleural Mesothelioma.Cancers (Basel)2024https://conductscience.org/library/papers/38610930PubMed
38052492Novel Anti-Mesothelin Nanobodies and Recombinant Immunotoxins with Pseudomonas Exotoxin Catalytic Domain for Cancer Therapeutics.Mol Cells2023https://conductscience.org/library/papers/38052492PubMed
37992257Targeted Approaches to Treatment of Pleural Mesothelioma: A Review.JCO Precis Oncol2023https://conductscience.org/library/papers/37992257PubMed
37869242Biology of Mesothelin and Clinical Implications: A Review of Existing Literature.World J Oncol2023https://conductscience.org/library/papers/37869242PubMed
37146241NAV-003, a bispecific antibody targeting a unique mesothelin epitope and CD3ε with improved cytotoxicity against humoral immunosuppressed tumors.Eur J Immunol2023https://conductscience.org/library/papers/37146241PubMed
36763234Targeting Mesothelin in Solid Tumours: Anti-mesothelin Antibody and Drug Conjugates.Curr Oncol Rep2023https://conductscience.org/library/papers/36763234PubMed
36669143Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti-PD-1 + Antiangiogenesis in Malignant Pleural Mesothelioma.Cancer Discov2023https://conductscience.org/library/papers/36669143PubMed

See all 38 cited byDownload CSV of cited by

Genes22

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CALR811PubTator's text mininghttps://conductscience.org/library/genes/811NCBI Gene
CCL26347PubTator's text mininghttps://conductscience.org/library/genes/6347NCBI Gene
CD24451744PubTator's text mininghttps://conductscience.org/library/genes/51744NCBI Gene
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920NCBI Gene
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925NCBI Gene
CRP1401PubTator's text mininghttps://conductscience.org/library/genes/1401NCBI Gene
CTLA41493PubTator's text mininghttps://conductscience.org/library/genes/1493NCBI Gene
CX3CL16376PubTator's text mininghttps://conductscience.org/library/genes/6376NCBI Gene
CXCL12919PubTator's text mininghttps://conductscience.org/library/genes/2919NCBI Gene
CXCL83576PubTator's text mininghttps://conductscience.org/library/genes/3576NCBI Gene
EEF21938PubTator's text mininghttps://conductscience.org/library/genes/1938NCBI Gene
EOMES8320PubTator's text mininghttps://conductscience.org/library/genes/8320NCBI Gene
IDO13620PubTator's text mininghttps://conductscience.org/library/genes/3620NCBI Gene
IFNG3458PubTator's text mininghttps://conductscience.org/library/genes/3458NCBI Gene
IL183606PubTator's text mininghttps://conductscience.org/library/genes/3606NCBI Gene
IL63569PubTator's text mininghttps://conductscience.org/library/genes/3569NCBI Gene
LAG33902PubTator's text mininghttps://conductscience.org/library/genes/3902NCBI Gene
MSLN10232PubTator's text mininghttps://conductscience.org/library/genes/10232NCBI Gene
PDCD15133PubTator's text mininghttps://conductscience.org/library/genes/5133NCBI Gene

See all 22 genesDownload CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32611684

GET https://conductscience.org/api/papers/v1/32611684/references?page=2